On September 15, 2025, aTyr Pharma reported that its Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis did not meet the primary endpoint of reducing corticosteroid dosage, showing a reduction to 2.79 mg compared to 3.52 mg for placebo (p=0.3313); however, there were improvements in lung function and quality of life measures, leading the company to plan further discussions with the FDA.